These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34814865)

  • 1. Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis.
    Jessen H; Hoyer N; Prior TS; Frederiksen P; Rønnow SR; Karsdal MA; Leeming DJ; Bendstrup E; Sand JMB; Shaker SB
    BMC Pulm Med; 2021 Nov; 21(1):382. PubMed ID: 34814865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis.
    Jessen H; Hoyer N; Prior TS; Frederiksen P; Karsdal MA; Leeming DJ; Bendstrup E; Sand JMB; Shaker SB
    Respir Res; 2021 Jul; 22(1):205. PubMed ID: 34261485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study.
    Jenkins RG; Simpson JK; Saini G; Bentley JH; Russell AM; Braybrooke R; Molyneaux PL; McKeever TM; Wells AU; Flynn A; Hubbard RB; Leeming DJ; Marshall RP; Karsdal MA; Lukey PT; Maher TM
    Lancet Respir Med; 2015 Jun; 3(6):462-72. PubMed ID: 25770676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort.
    Organ LA; Duggan AR; Oballa E; Taggart SC; Simpson JK; Kang'ombe AR; Braybrooke R; Molyneaux PL; North B; Karkera Y; Leeming DJ; Karsdal MA; Nanthakumar CB; Fahy WA; Marshall RP; Jenkins RG; Maher TM
    Respir Res; 2019 Jul; 20(1):148. PubMed ID: 31299951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High turnover of types III and VI collagen in progressive idiopathic pulmonary fibrosis.
    Hoyer N; Jessen H; Prior TS; Sand JMB; Leeming DJ; Karsdal MA; Åttingsberg EKA; Vangsgaard GKM; Bendstrup E; Shaker SB
    Respirology; 2021 Jun; 26(6):582-589. PubMed ID: 33834579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD.
    Bihlet AR; Karsdal MA; Sand JM; Leeming DJ; Roberts M; White W; Bowler R
    Respir Res; 2017 Jan; 18(1):22. PubMed ID: 28103932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collagen Type III and VI Turnover in Response to Long-Term Immobilization.
    Sun S; Henriksen K; Karsdal MA; Byrjalsen I; Rittweger J; Armbrecht G; Belavy DL; Felsenberg D; Nedergaard AF
    PLoS One; 2015; 10(12):e0144525. PubMed ID: 26641456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
    Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
    Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib modulates type III collagen turnover in viable precision-cut lung slices from bleomycin-treated rats and patients with pulmonary fibrosis.
    Hesse C; Beneke V; Konzok S; Diefenbach C; Bülow Sand JM; Rønnow SR; Karsdal MA; Jonigk D; Sewald K; Braun A; Leeming DJ; Wollin L
    Respir Res; 2022 Aug; 23(1):201. PubMed ID: 35927669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan.
    Ikeda K; Chiba H; Nishikiori H; Azuma A; Kondoh Y; Ogura T; Taguchi Y; Ebina M; Sakaguchi H; Miyazawa S; Suga M; Sugiyama Y; Nukiwa T; Kudoh S; Takahashi H;
    Respir Res; 2020 Nov; 21(1):316. PubMed ID: 33256760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LPA
    Decato BE; Leeming DJ; Sand JMB; Fischer A; Du S; Palmer SM; Karsdal M; Luo Y; Minnich A
    Respir Res; 2022 Mar; 23(1):61. PubMed ID: 35303880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.
    Maher TM; Oballa E; Simpson JK; Porte J; Habgood A; Fahy WA; Flynn A; Molyneaux PL; Braybrooke R; Divyateja H; Parfrey H; Rassl D; Russell AM; Saini G; Renzoni EA; Duggan AM; Hubbard R; Wells AU; Lukey PT; Marshall RP; Jenkins RG
    Lancet Respir Med; 2017 Dec; 5(12):946-955. PubMed ID: 29150411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis.
    Adegunsoye A; Alqalyoobi S; Linderholm A; Bowman WS; Lee CT; Pugashetti JV; Sarma N; Ma SF; Haczku A; Sperling A; Strek ME; Noth I; Oldham JM
    Chest; 2020 Oct; 158(4):1526-1534. PubMed ID: 32450241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated plasma proteomics and lung transcriptomics reveal novel biomarkers in idiopathic pulmonary fibrosis.
    Sivakumar P; Ammar R; Thompson JR; Luo Y; Streltsov D; Porteous M; McCoubrey C; Cantu E; Beers MF; Jarai G; Christie JD
    Respir Res; 2021 Oct; 22(1):273. PubMed ID: 34689792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab.
    Nissen NI; Kehlet S; Boisen MK; Liljefors M; Jensen C; Johansen AZ; Johansen JS; Erler JT; Karsdal M; Mortensen JH; Høye A; Willumsen N
    Sci Rep; 2021 Jan; 11(1):865. PubMed ID: 33441622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
    Noor S; Nawaz S; Chaudhuri N
    Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation.
    Fainberg HP; Moodley Y; Triguero I; Corte TJ; Sand JMB; Leeming DJ; Karsdal MA; Wells AU; Renzoni E; Mackintosh J; Tan DBA; Li R; Porte J; Braybrooke R; Saini G; Johnson SR; Wain LV; Molyneaux PL; Maher TM; Stewart ID; Jenkins RG
    Lancet Respir Med; 2024 Sep; 12(9):681-692. PubMed ID: 39025091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of serological neo-epitope biomarkers reflecting collagen remodeling in clinically stable chronic obstructive pulmonary disease.
    Sand JM; Martinez G; Midjord AK; Karsdal MA; Leeming DJ; Lange P
    Clin Biochem; 2016 Oct; 49(15):1144-1151. PubMed ID: 27614218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.